Capricor Therapeutics Inc [CAPR] stock is trading at $6.76, up 5.79%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CAPR shares have gain 16.55% over the last week, with a monthly amount glided 79.31%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Capricor Therapeutics Inc [NASDAQ: CAPR] stock has seen the most recent analyst activity on January 05, 2024, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $8. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on October 26, 2022, and set its price target to $15. On December 26, 2018, downgrade downgraded it’s rating to Hold. H.C. Wainwright reiterated its Buy rating and increased its price target to $8.60 on January 26, 2018. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $6.50 on September 15, 2017.
Capricor Therapeutics Inc [CAPR] stock has fluctuated between $2.68 and $8.22 over the past year. Capricor Therapeutics Inc [NASDAQ: CAPR] shares were valued at $6.76 at the most recent close of the market.
Analyzing the CAPR fundamentals
Capricor Therapeutics Inc [NASDAQ:CAPR] reported sales of 25.18M for the trailing twelve months, which represents a growth of 1159.30%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.95%, Pretax Profit Margin comes in at -0.89%, and Net Profit Margin reading is 15.65%. To continue investigating profitability, this company’s Return on Assets is posted at 6.71, Equity is 52.99 and Total Capital is -0.87. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.27 points at the first support level, and at 5.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.08, and for the 2nd resistance point, it is at 7.40.
Ratios To Look Out For
For context, Capricor Therapeutics Inc’s Current Ratio is 1.63. Also, the Quick Ratio is 1.63, while the Cash Ratio stands at 0.47. Considering the valuation of this stock, the price to sales ratio is 8.43, the price to book ratio is 9.32.
Transactions by insiders
Recent insider trading involved Musket David B, Director, that happened on Oct 12 ’23 when 410.0 shares were purchased. Director, COLLIER EARL M JR completed a deal on Oct 10 ’23 to buy 10000.0 shares. Meanwhile, Director Musket David B bought 5083.0 shares on Oct 09 ’23.
